A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-144/LN-145) in Patients with Solid Tumors
Study of LN-145 in the Treatment of Squamous Cell Carcinoma of the Head & Neck or Non Small Cell Lung Cancer (NSCLC)
Sponsor: Iovance Biotherapeutics, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAS5355
U.S. Govt. ID: NCT03645928
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this clinical research study is to find out if an Investigational Drug, called LN-144/LN-145, is safe and beneficial in the treatment of participants with Metastatic Melanoma, or head and neck squamous cell carcinoma (HNSCC) when given in combination with a medication, named pembrolizumab (Keytruda), or in participants with non-small cell lung cancer (NSCLC), when LN-144/LN-145 is given alone as a single therapy. The LN-144/LN-145 Study drug is made up of specialized white blood cells called lymphocytes or T cells that are derived from your tumor after a small piece is obtained by surgical removal. This piece of your own tumor is sent to a centralized manufacturing facility where T cells that have infiltrated your tumor are isolated and grown to create the study drug LN-144/LN-145, which are infused back into your body.
This study is closed
Richard Carvajal, MD
Do You Qualify?
Do you have a melanoma, head and neck squamous cell carinoma (HNSCC), or non-small cell lung cancer (NSCLC)? Yes No
Does your cancer continue to grow or cannot be removed by surgery? Yes No
Are you 18 years of age or older and younger than 70 years of age? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator